Adipose triglyceride lipase (ATGL) is rate-limiting in the mobilization of fatty acids from cellular triglyceride stores.Given that dyslipidemic and metabolic disorders are closely related to uncontrolled fatty acid metabolism, ATGL's central role in lipolysis makes it an intriguing pharmacological target. In this article, we discuss the creation and evaluation of a small-molecule ATGL inhibitor. In vitro and in vivo, atglistatin reduces fatty acid mobilization and is selective for ATGL. Triacylglycerol (TG) is broken down first by ATGL into diacylglycerol, which is then broken down further by hormone-sensitive lipase (HSL) and monoglyceride lipase (MGL) into glycerol and fatty acids (FA).
The two main enzymes that contribute to the breakdown of triacylglycerol (TG) in in vitro assays and organ cultures of murine white adipose tissue (WAT) are adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V60134 | NG-497 | 2598242-66-9 | NG-497 is a human adipose triglyceride lipase (ATGL) tumor suppressor that can inhibit the enzyme-promoting active patatin-like domain of human ATGL. |
|
V1958 | Atglistatin | 1469924-27-3 | Atglistatin is a highly potent and selective inhibitor of adipose triglyceride lipase (ATGL) with IC50 of 0.7 μM, it showed high selectivity over other key metabolic lipases. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
